HAARLEM, Netherlands & PHILADELPHIA, PA — Spaarne Gasthuis, a leading clinical teaching hospital serving part of the Greater Amsterdam region, announced it is fully digitizing its pathology practice with Concentriq® AP-Dx* from Proscia®. The move positions the hospital to advance precision medicine and improve collaboration across its network of clinicians and researchers.
“We are committed to providing highly specialized care to every patient, and that almost always starts with a precise, timely diagnosis,” said Timo van Dam, Head of the Pathology Department at Spaarne Gasthuis. “Choosing Proscia was a decision we approached carefully, and we are confident its team will be a strategic, long-term partner. Its software will grow with our needs, its people are invested in our success, and its bold vision will help keep us at the forefront of our field.”
Spaarne Gasthuis will use Concentriq AP-Dx for primary diagnosis and collaboration, driving efficiency and expanding access to expertise. The platform allows cases to be rapidly shared with subspecialists and peers at other hospitals, including members of the OncoNoVo+ regional cancer network and fellow Proscia customer, the Netherlands Cancer Institute.
An open, cloud-based platform, Concentriq AP-Dx gives Spaarne Gasthuis flexibility in selecting scanners and AI applications, while tightly integrating with the hospital’s laboratory information system to streamline workflows and accelerate the transition away from microscopes.
“Fully digitizing its practice from day one speaks volumes about Spaarne Gasthuis’ approach to AI-driven pathology,” said David West, CEO of Proscia. “The team recognizes the value and is eager to deliver it to patients. As an academic medical center, it is also well positioned to build on this foundation to advance the scientific research it conducts.”
Pathology images provide one of the most detailed views of diseases such as cancer, offering key insights that can advance research and support the development of next-generation AI tools. Proscia’s broader portfolio enables organizations to unlock the full potential of pathology data—from drug discovery to diagnostics—helping reshape how diseases are studied and treated.
Concentriq AP-Dx is FDA-cleared for primary diagnosis in the United States with the Hamamatsu NanoZoomer® S360MD Slide scanner and is licensed in Canada and CE-marked under the EU IVDR for primary diagnosis. Concentriq AP-Dx is not intended for use with frozen sections, cytology, or non-FFPE hematopathology specimens.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.